Shuttle Pharmaceuticals (SHPH) announced that the first three patients in its Phase 2 Clinical Trial of Ropidoxuridine for the treatment of patients with glioblastoma have been successfully dosed. “The initiation of patient dosing in our Phase 2 trial of Ropidoxuridine for the treatment of patients with glioblastoma is a significant milestone for both Shuttle Pharma and the thousands of patients with brain tumors who currently lack effective therapies,” commented Shuttle Pharma’s Chairman and CEO, Anatoly Dritschilo, M.D. “The results of this trial will be important as Shuttle Pharma looks to leverage radiation sensitizers to increase cancer cure rates, prolong patient survival and improve quality of life for patients suffering from glioblastoma.”
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on SHPH:
- Shuttle Pharmaceuticals Advances Glioblastoma Clinical Trials
- Shuttle’s clinical trial site enrollments complete for Phase 2 of IPdR for GBM
- Shuttle Pharmaceuticals to Present at ThinkEquity Conference
- Shuttle Pharmaceuticals files to sell common stock, warrants, no amount given
- Shuttle Pharmaceuticals expands clinical trial site enrollment for Phase 2 trial